NMOSD is a relapsing autoimmune disease where early diagnosis and rapid initiation of effective long-term therapy are essential to prevent irreversible disability driven by attacks.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare but severe relapsing disease of the central nervous system, characterized by attacks that lead to cumulative disability. Unlike multiple sclerosis, progression is not continuous but driven by relapses, making early diagnosis and rapid treatment essential. Advances in biomarkers, classification, and targeted therapies are reshaping how clinicians approach NMOSD management.
Key Insights from the Lecture:
- NMOSD is a rare but globally variable disease
- Disability is driven by relapses, not progression
- Aquaporin-4 antibodies are central to diagnosis
- Disease classification is evolving
- Treatment has three key pillars
- Early treatment of relapses is essential
- Long-term therapy must start early
- Biologic therapies are transforming care
- Treatment choice depends on access and patient context
- Monitoring and safety remain critical
“The Clinical Management of NMOSD”.
Please subscribe to watch.
About the speaker:
Jelena Drulovic
Professor of Neurology at the Faculty of Medicine, University of Belgrade
Media
Details
We value your opinion.
